Blueprint Medicines Corp reports results for the quarter ended in March - Earnings Summary

Blueprint Medicines

04/05/2023 15:48

* Blueprint Medicines Corp  BPMC.OQ  reported a quarterly
adjusted
loss of $2.15​​ per share for the quarter ended in March. The
mean expectation of seventeen analysts for the quarter was for a
loss of $2.67 per share.
    * Revenue rose 0.9% to $63.29 million from a year ago;
analysts
expected $41.96 million. 
    * Blueprint Medicines Corp's reported EPS for the quarter
was a
loss of $2.15​.
    * The mean earnings estimate of analysts had fallen by
about 3.2%
in the last three months.​ 
    * In the last 30 days, seven analysts negatively revised
earnings
estimates 
    * Blueprint Medicines Corp shares had risen by 15.3% this
quarter and gained 18.4% so far this year.
    * The company reported a quarterly loss of $129.56 million.
    * Wall Street's median 12-month price target for Blueprint
Medicines Corp is $70.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," 6
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
4 at 02:48 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -2.67          -2.15          Beat
 Dec. 31 2022      -2.65          -2.65          Met
 Sep. 30 2022      -2.49          -2.23          Beat
 Jun. 30 2022      -2.23          -2.68          Missed